Holen Sie sich die Stockscreener-App
29.58
1.40%
-0.42
Handel nachbörslich:
29.50
-0.08
-0.27%
Ideaya Biosciences Inc Aktie (IDYA) Neueste Nachrichten
IDEAYA Biosciences (NASDAQ:IDYA) Shares Down 4.5%Here's What Happened - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Releases Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Leerink Partners Downgrades IDEAYA Biosciences (NASDAQ:IDYA) to Market Perform - MarketBeat
Wedbush Reiterates "Outperform" Rating for IDEAYA Biosciences (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences: Q3 2024 Financial and Clinical Progress - TipRanks
/C O R R E C T I O N -- IDEAYA Biosciences, Inc./ - Yahoo Finance
IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update - PR Newswire
abrdn plc Buys Shares of 232,830 IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Ideaya Biosciences stock hits 52-week low at $28.04 By Investing.com - Investing.com South Africa
IDEAYA Biosciences (NASDAQ:IDYA) Reaches New 1-Year LowHere's What Happened - MarketBeat
Ideaya Biosciences stock hits 52-week low at $28.04 - Investing.com
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - StockTitan
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinic - GuruFocus.com
Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to Decline - MSN
IDEAYA Biosciences' (IDYA) "Outperform" Rating Reaffirmed at Oppenheimer - MarketBeat
IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors - The Malaysian Reserve
IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors – Company Announcement - Financial Times
IDEAYA Biosciences Announces IND-Clearance for Werner Helicase D - GuruFocus.com
IDEAYA Biosciences Reports Encouraging Clinical Data for IDE397 in MTAP-Deletion Urothelial Cancer and NSCLC - Defense World
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $55.45 Average Price Target from Brokerages - MarketBeat
IDYAIDEAYA Biosciences, Inc. Latest Stock News & Market Updates - StockTitan
IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024 - Quantisnow
Leerink Partnrs Has Pessimistic View of IDYA Q3 Earnings - MarketBeat
UBS Group Initiates Coverage on IDEAYA Biosciences (NASDAQ:IDYA) - MarketBeat
Where are the Opportunities in (IDYA) - Stock Traders Daily
Analysts Offer Predictions for IDYA FY2024 Earnings - MarketBeat
Cantor Fitzgerald Initiates Coverage on IDEAYA Biosciences (NASDAQ:IDYA) - Defense World
Investor’s Delight: Ideaya Biosciences Inc (IDYA) Closes Strong at 30.82, Up 1.15 - The Dwinnex
Cantor Fitzgerald initiates coverage on Ideaya Biosciences shares with Overweight rating - Investing.com Canada
IDEAYA Biosciences (NASDAQ:IDYA) Now Covered by Analysts at Cantor Fitzgerald - MarketBeat
Ideaya Biosciences Inc (IDYA) stock on the rise: An overview - US Post News
Trend Tracker for (IDYA) - Stock Traders Daily
IDEAYA Biosciences (NASDAQ:IDYA) Shares Down 3.7%Here's What Happened - MarketBeat
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Sold by Healthcare of Ontario Pension Plan Trust Fund - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Trading 5.6% HigherStill a Buy? - MarketBeat
Investing in Ideaya Biosciences Inc (IDYA): What You Must Know - Knox Daily
Algert Global LLC Sells 24,193 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium - The Malaysian Reserve
IDEAYA presents phase 1 cancer drug results in Barcelona - Investing.com
IDEAYA presents phase 1 cancer drug results in Barcelona By Investing.com - Investing.com Australia
IDEAYA Biosciences (NASDAQ:IDYA) Shares Down 6.2% - MarketBeat
Envestnet Asset Management Inc. Raises Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Squarepoint Ops LLC Has $3.53 Million Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Stock Position Increased by Logos Global Management LP - MarketBeat
(IDYA) Investment Analysis - Stock Traders Daily
IDEAYA Biosciences' SWOT analysis: promising pipeline drives stock outlook - Investing.com India
109,325 Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Acquired by Renaissance Technologies LLC - MarketBeat
Scientech Research LLC Boosts Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Ideaya Biosciences announces inducement grants under Nasdaq listing rule - TipRanks
Ideaya Biosciences Stock Tumbles Despite Promising Data From Rare Eye Cancer Candidate - MSN
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Forecasted to Earn FY2025 Earnings of ($3.49) Per Share - MarketBeat
Deerfield Management Company L.P. Series C Sells 533,179 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Mizuho keeps stock target, outperform on Ideaya Biosciences, cites FDA update - Investing.com Canada
Ideaya Biosciences Inc (IDYA)’s results reveal risk - US Post News
RBC maintains price target on Ideaya Biosciences, upbeat on daro By Investing.com - Investing.com Canada
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):